February 10, 2026·3 min read·methodology, literature
How to read a peptide study
A compact framework for evaluating a peptide paper — what to check, what to discount, and how to tell mechanism from marketing.
A compact framework for evaluating a peptide paper — what to check, what to discount, and how to tell mechanism from marketing.
Most of the confident claims you see online about peptides trace back to two or three papers, often misread, occasionally cherry-picked, and sometimes pre-clinical work in rodents repackaged as human dosing guidance. A short checklist for separating signal from confidence theater. This framework applies to evaluating claims in research-grade specifications, lab reports, and any marketing material citing peptide studies.
The first thing to note about any peptide paper is what system it was run in. In vitro work in a cell culture tells you a compound can bind a receptor. It does not tell you it will reach that receptor after subcutaneous injection. Rodent work is more predictive, but route of administration, body composition, and half-life all differ — a compound that works IP in a mouse may not produce the same pharmacokinetic curve subcutaneously in a human.
Human data trumps everything, but there is less of it than the internet suggests. If the human data is a 12-person crossover, treat it as a hypothesis generator, not a protocol.
Allometric scaling — converting from mouse mg/kg to human equivalent — is not optional. Papers doing it wrong are common. Look for the Reagan-Shaw formula (or a similar body-surface-area correction). If the paper jumps directly from mouse mg/kg to human mg/kg without scaling, the dose estimates in the abstract are likely 10x too high.
A peptide paper will usually have a mechanism section (it binds this receptor, activates this pathway) and an outcome section (subjects lost weight, recovered faster, slept better). Mechanism claims are easier to verify but don't guarantee the outcome. Outcome claims matter more but are noisier.
If a compound has a strong mechanism story and weak outcome data, you're looking at an early-stage hypothesis. If it has strong outcome data but a fuzzy mechanism, the effect is probably real but the reason may be different from what the authors proposed.
Not to dismiss industry-funded work — much of the best peptide literature comes from pharmaceutical companies with deep resources. But read the conflict-of-interest disclosure and the methods section with that context.
One paper is a data point. Two papers with similar methodology and converging results is a trend. Three is where it starts to matter. Any confident dosing recommendation you see online that cites a single source should be discounted.
How do you evaluate the quality of a peptide research paper? Check the species and tissue tested (in vitro vs rodent vs human), verify dose conversions using body-surface-area correction (Reagan-Shaw formula), separate mechanism claims from outcome claims, check funding and conflicts of interest, and cross-reference with at least two other papers. One paper is a data point; three papers with converging results is where it starts to matter.
Why is species important when reading peptide literature? Rodent studies are more predictive than in vitro work, but route of administration, body composition, and half-life all differ between species. A compound that works intraperitoneally in mice may not work subcutaneously in humans. Always check what species was used and what route was tested.
What is allometric scaling and why does it matter in peptide research? Allometric scaling uses body-surface-area correction formulas (like Reagan-Shaw) to convert mouse mg/kg doses to human equivalents. Without proper scaling, raw mg/kg numbers are often 10x too high. If a paper jumps directly from mouse to human dosing without scaling, discount the dose estimates.
How many papers should you read before trusting a peptide claim? One paper is insufficient — it's a hypothesis generator, not a protocol. Two papers with similar methodology and converging results suggests a trend. Three papers is where confidence begins. Any confident dosing recommendation you see online citing only a single source should be heavily discounted.